Life sciences · Journal article
Cancer Discovery · October 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Neuroendocrine differentiation (NED) promotes lineage plasticity and therapy resistance in prostate and lung cancers. Here we identify NED as a route of treatment escape in breast cancer: neuroendocrine features emerged or increased in 22% of progressive cases, predominantly, but not exclusively, in HER2-positive subtype. Using patient-derived, epithelial/neuroendocrine organoid and xenograft models, we map the epigenetic and transcriptional divergence between epithelial and neuroendocrine states arising from a shared mutational background and define a breast cancer neuroendocrine signature. NED involves epigenetic silencing of EpCAM and amplified HER2, while NEUROD1 functions as a master transcriptional regulator of the neuroendocrine fate. NCAM-positive putative circulating tumor cells were detected in patients in whom EpCAM-based detection had failed. Neuroendocrine tumor cells exhibit an FGFR1 dependency associated with NCAM-FGFR1 interaction and mesenchymal FGFR1 splicing. Together, these findings establish NED as a mechanism of escape from HER2-targeted therapy in breast cancer, with implications for disease monitoring and intervention.